Loading clinical trials...
Loading clinical trials...
A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged With Influenza A/Perth/16/2009 (H3N2) Virus
Conditions
Interventions
PrEP-001
Placebo Comparator
Locations
1
United Kingdom
hVIVO Services Ltd, QMB Bioenterprise building
London, United Kingdom
Start Date
September 16, 2015
Primary Completion Date
February 1, 2016
Completion Date
February 1, 2016
Last Updated
November 12, 2019
Lead Sponsor
Hvivo
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions